Company: SRPT
Filing Date: 2025-02-14
Form Type: 8-K
Source: 0001193125-25-026683
Chunk: 3

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01      Financial Statements and Exhibits.  

(d) Exhibits

  Exhibit      Description                                                                                                                                                                                           
                                                                                                                                                                                                                     
   Number                                                                                                                                                                                                            
     10.1      Credit Agreement, dated February 13, 2025, among Sarepta Therapeutics, Inc., Sarepta Therapeutics Investments, Inc., JPMorgan Chase Bank, N. A., as administrative agent, and the lenders party t...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101                                                               

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        Sarepta Therapeutics, Inc.             
  Date: February 14, 2025      By:      /s/ Douglas S. Ingram                  
                                        Douglas S. Ingram